The Nonalcoholic Steatohepatitis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Nonalcoholic Steatohepatitis: An Overview
Nonalcoholic Steatohepatitis (NASH) is the progressive form of liver injury that carries a risk of progressive fibrosis, cirrhosis, and end-stage liver disease. It is an advanced form of nonalcoholic fatty liver disease (NAFLD), caused by the buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life-threatening condition called cirrhosis.
NASH usually comes under the category of silent diseases that has very few or no symptoms typically because it does not cause any symptoms until it is too late. In the early period, patients did not complain about anything specific. Even with the advancing fibrosis, the disease may not have any specific problems. However, in the later stages, patients may start developing some non-specific symptoms.
Nonalcoholic Steatohepatitis Market Key Facts
-
Of all the prevalent cases of NAFLD in the 7MM, approximately 19% of the population fulfilled the criteria for NASH. These cases are expected to increase throughout the study period.
-
As per DelveInsight, the highest prevalence of NASH in the United States, accounting for close to 50% of the total prevalent cases, followed by Japan.
-
It is observed that among the European countries, Germany accounted for the highest prevalent population, followed by Italy. Among all the 7MM countries, Spain had the lowest prevalent population.
-
DelveInsight’s estimations suggest that of the total diagnosed patients in the United States, F4 accounts for the maximum number in the patient pool (~60%), while F0 had the least reported cases.
Nonalcoholic Steatohepatitis Market
Nonalcoholic Steatohepatitis (NASH) market size is expected to increase during the forecast period owing to the launch of upcoming therapies. The expected launch of emerging therapies will fill the void in treatment areas shortly. The targeted therapies will have stronger penetration than the off-label therapies. The advancement in diagnostic technologies for NASH will also significantly influence the market size.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Nonalcoholic Steatohepatitis market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the Nonalcoholic Steatohepatitis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Nonalcoholic Steatohepatitis Epidemiology
The epidemiology section provides insights into the historical and current Nonalcoholic Steatohepatitis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool, future trends, and assumptions undertaken.
Nonalcoholic Steatohepatitis (NASH) Epidemiology Segmentation –
-
Total Prevalent Cases of Non-Alcoholic Fatty Liver Disease
-
Total Prevalent cases of Nonalcoholic Steatohepatitis
-
Nonalcoholic Steatohepatitis Segmentation by Fibrosis Stage
Nonalcoholic Steatohepatitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Nonalcoholic Steatohepatitis market or expected to get launched during the study period. The analysis covers Nonalcoholic Steatohepatitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Nonalcoholic Steatohepatitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market
Nonalcoholic Steatohepatitis Therapeutics Analysis
The treatment of NASH depends on the stage of the disease. Currently, there is no approved therapy for the treatment of NASH, yet doctors prescribe certain off-label drugs (supportive therapies) for its management. Lifestyle modifications are, however, the first line of treatment. Lifestyle modifications include going for weight loss combined with an active exercise program along with a planned diet.
Some of the key companies in the Nonalcoholic Steatohepatitis (NASH) Market include:
-
Genfit
-
Intercept Pharmaceuticals
-
Allergan (Tobira Therapeutics)
-
Gilead Sciences
-
Galmed Pharmaceuticals Ltd.
-
Bristol-Myers Squibb (BMS)
-
Immuron
-
Galectin Therapeutics
-
Cirius Therapeutics
-
NGM Biopharmaceuticals
-
TaiwanJ Pharmaceuticals
-
Novo Nordisk
-
Mitsubishi Tanabe Pharma
-
Novartis Pharmaceuticals
-
MediciNova
-
Madrigal Pharmaceuticals
-
Can-Fite BioPharma
-
Oramed Pharmaceuticals
-
Ascletis Pharma
-
Terns Pharmaceuticals
-
Enyo Pharma
And many others.
Nonalcoholic Steatohepatitis (NASH) Therapies covered in the report include:
-
Elafibranor (GFT505)
-
Obeticholic Acid (OCA, Ocaliva)
-
Selonsertib (SEL, Formerly GS-4997)
-
Cenicriviroc (CVC)
-
Cilofexor (GS-9674)
-
Firsocostat (GS-0976)
-
Aramchol
-
Pegbelfermin (BMS-986036)
-
IMM-124E
-
Belapectin (GR-MD-02)
-
MSDC-0602K
-
NGM282 (aldafermin)
-
JKB-122
-
Semaglutide
-
MT-3995 (Apararenone)
-
LJC242
-
LJN452 (Tropifexor)
-
MN-001 (Tipelukast)
-
Resmetirom (MGL-3196)
-
Namodenoson (CF102)
-
ORMD-0801
-
ASC40
-
TERN-101
-
EYP001
And many more
Get More Detailed Insights Into the Emerging Therapies & Key Companies –
https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Nonalcoholic Steatohepatitis Competitive Intelligence Analysis
4. Nonalcoholic Steatohepatitis Market Overview at a Glance
5. Nonalcoholic Steatohepatitis Disease Background and Overview
6. Nonalcoholic Steatohepatitis Patient Journey
7. Nonalcoholic Steatohepatitis Epidemiology and Patient Population
8. Nonalcoholic Steatohepatitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Nonalcoholic Steatohepatitis Unmet Needs
10. Key Endpoints of Nonalcoholic Steatohepatitis Treatment
11. Nonalcoholic Steatohepatitis Marketed Products
12. Nonalcoholic Steatohepatitis Emerging Therapies
13. Nonalcoholic Steatohepatitis Seven Major Market Analysis
14. Attribute Analysis
15. Nonalcoholic Steatohepatitis Market Outlook (7 major markets)
16. Nonalcoholic Steatohepatitis Access and Reimbursement Overview
17. KOL Views on the Nonalcoholic Steatohepatitis Market.
18. Nonalcoholic Steatohepatitis Market Drivers
19. Nonalcoholic Steatohepatitis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report –
https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Other Latest Reports By DelveInsight
Radiofrequency Ablation Devices Market
Global Radiofrequency Ablation Devices Market was valued at USD 3.35 billion in 2020, growing at a CAGR of 9.34% during the forecast period from 2021 to 2026 to reach USD 5.69 billion by 2026. Some of the key companies in the Radiofrequency Ablation Devices Market include BIOTRONIK Schweiz AG, Medtronic, Abbott, Olympus., Stryker, Boston Scientific Corporation, AngioDynamics., CONMED Corporation, Lepu Medical Technology (Beijing), and others.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/